Xenon Pharmaceuticals Inc. Other Research and Development Expense
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-06
- Xenon Pharmaceuticals Inc. other research and development expense for the quarter ending 2026-06-30 was $4.64M, a 78.54% increase year-over-year.
- Xenon Pharmaceuticals Inc. other research and development expense for the quarter ending 2026-03-31 was $4.20M, a 22.66% increase year-over-year.
- Xenon Pharmaceuticals Inc. other research and development expense for the quarter ending 2025-12-31 was $3.77M, a 161.30% increase year-over-year.
- Xenon Pharmaceuticals Inc. other research and development expense for the quarter ending 2025-09-30 was $2.73M, a 24.55% decline year-over-year.
- Xenon Pharmaceuticals Inc. other research and development expense for fiscal 2025 was $12.52M, a 11.46% increase from fiscal 2024.
- Xenon Pharmaceuticals Inc. other research and development expense for fiscal 2024 was $11.23M, a 17.49% increase from fiscal 2023.
- Xenon Pharmaceuticals Inc. other research and development expense for fiscal 2023 was $9.56M, a 31.43% increase from fiscal 2022.
- Xenon Pharmaceuticals Inc. other research and development expense for fiscal 2022 was $7.27M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.64M 10-Q · filed 2026-08-06 | $8.84M 10-Q · filed 2026-08-06 | $12.61M derived: sum of 3 quarters · filed 2026-08-06 | $15.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-07 | $7.97M derived: sum of 2 quarters · filed 2026-05-07 | $10.70M derived: sum of 3 quarters · filed 2026-05-07 | $13.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.49M derived: sum of 2 quarters · filed 2026-02-26 | $9.09M derived: sum of 3 quarters · filed 2026-08-06 | $12.52M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-03 | $5.33M derived: sum of 2 quarters · filed 2026-08-06 | $8.75M 10-Q · filed 2025-11-03 | $10.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.60M 10-Q · filed 2026-08-06 | $6.03M 10-Q · filed 2026-08-06 | $7.47M derived: sum of 3 quarters · filed 2026-08-06 | $11.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.42M 10-Q · filed 2026-05-07 | $4.87M derived: sum of 2 quarters · filed 2026-05-07 | $8.48M derived: sum of 3 quarters · filed 2026-05-07 | $11.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.05M derived: sum of 2 quarters · filed 2026-02-26 | $8.22M derived: sum of 3 quarters · filed 2026-02-26 | $11.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.61M 10-Q · filed 2025-11-03 | $6.78M derived: sum of 2 quarters · filed 2025-11-03 | $9.79M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $3.16M 10-Q · filed 2025-08-11 | $6.18M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $3.01M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $9.56M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $7.27M 10-K · filed 2025-02-27 |